Anterix insider corrects reported stock option balance

Anterix Inc. executive Christopher Guttman-McCabe updated his reported stock option holdings to correct a previously misreported balance.

Accepted by SEC EDGAR 07/10/2026 - 04:13 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Anterix Inc. executive Christopher Guttman-McCabe updated his reported stock option holdings to correct a previously misreported balance. The amended disclosure shows a fully vested stock option to purchase 50,876 shares of common stock at an exercise price of $34.40 per share, expiring on October 21, 2030. No new option grants, exercises, sales, or other transactions are reported; only the number of securities held was corrected.

Insider Trade Summary

Holdings reported, no transactions

Holdings

Insider Guttman-McCabe Christopher

Role Chief Reg & Comm Officer

Type	Security	Shares	Price	Value
Holding	Stock Option (Right to Buy) F1, F2	--	--	--

Holdings: Stock Option (Right to Buy) — 50,876 options (Direct)

Footnotes (2)

1. F1. The option shares are fully vested.
2. F2. This Form 4/A amends the Form 4 filed by the reporting person on June 17, 2026 (the "Original Form 4"), which inadvertently reported the incorrect number of securities in column 9 of Table II. This Form 4/A is being filed solely to correct the number of securities reported in column 9 of Table II. No other amendments or changes have been made to the Original Form 4.

Key Figures

Underlying option shares: 50,876 shares Exercise price: $34.40 per share Expiration date: October 21, 2030

3 metrics

Underlying option shares 50,876 shares Underlying common shares for fully vested stock option held directly

Exercise price $34.40 per share Exercise price of the reported stock option position

Expiration date October 21, 2030 Expiration date of the stock option (Right to Buy)

Key Terms

Stock Option (Right to Buy), fully vested, Table II

3 terms

Stock Option (Right to Buy) financial

"The security title is reported as Stock Option (Right to Buy)."

fully vested financial

"The option shares are fully vested."

Table II regulatory

"incorrect number of securities in column 9 of Table II."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Anterix (ATEX) executive Christopher Guttman-McCabe report in this amended Form 4?

Christopher Guttman-McCabe corrected his reported stock option holdings. The amended report shows a fully vested option for 50,876 shares of Anterix common stock at an exercise price of $34.40 per share, expiring on October 21, 2030.

Does this Anterix (ATEX) Form 4/A show any insider buying or selling?

No insider buying or selling is shown. The report reflects a holding entry correcting the number of option shares in a prior filing, with no new grants, exercises, or sales disclosed.

How many Anterix (ATEX) shares are covered by Christopher Guttman-McCabe’s option?

The option covers 50,876 shares of Anterix common stock. This figure represents the underlying shares for a fully vested stock option position reported as held directly following the correction.

What is the exercise price and expiration date of the Anterix (ATEX) option reported?

The reported stock option has an exercise price of $34.40 per share and an expiration date of October 21, 2030. These terms apply to 50,876 underlying shares of Anterix common stock.

Why was this Anterix (ATEX) insider report amended?

The report was amended to correct the number of securities shown in column 9 of Table II in a prior Form 4. The amendment states no other changes were made beyond this numerical correction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Guttman-McCabe Christopher

(Last) (First) (Middle)

3 GARRET MOUNTAIN PLAZA

SUITE 401

(Street)

WOODLAND PARK NEW JERSEY 07424

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Anterix Inc. [ ATEX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Reg & Comm Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)
06/17/2026

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$34.4							(1)	10/21/2030	Common Stock	50,876		11,624(2)	D

Explanation of Responses:

1. The option shares are fully vested.

2. This Form 4/A amends the Form 4 filed by the reporting person on June 17, 2026 (the "Original Form 4"), which inadvertently reported the incorrect number of securities in column 9 of Table II. This Form 4/A is being filed solely to correct the number of securities reported in column 9 of Table II. No other amendments or changes have been made to the Original Form 4.

Remarks:

	/s/ Gena L. Ashe	07/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)